

Thomas B Casale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3903744/publications.pdf>

Version: 2024-02-01

362
papers

24,777
citations

11651

70
h-index

8396

147
g-index

375
all docs

375
docs citations

375
times ranked

15595
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of combined symptom& medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
2	Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma. New England Journal of Medicine, 2022, 386, 1505-1518.	27.0	40
3	Allergen immunotherapy in MASK&air users in real&life: Results of a Bayesian mixed&effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
4	Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment. International Journal of Molecular Sciences, 2022, 23, 3881.	4.1	6
5	Clinical and molecular implications of RGS2 promoter genetic variation in severe asthma. Journal of Allergy and Clinical Immunology, 2022, 150, 721-726.e1.	2.9	1
6	Comparison of rhinitis treatments using <sc>MASK</sc>&air& data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
7	Acute At-Home Management of Anaphylaxis: 911: What Is the Emergency?. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2274-2279.	3.8	13
8	A Close Look at Vaping in Adolescents and Young Adults in the USA. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	8
9	EAACI Biologicals Guidelines& Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	5.7	156
10	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
11	ARIA&EAACI statement on asthma and COVID&19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
12	Targeted Molecular Therapies in Allergy and Rhinology. Otolaryngology - Head and Neck Surgery, 2021, 164, S1-S21.	1.9	18
13	How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1081-1088.	3.8	28
14	A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial. Contemporary Clinical Trials, 2021, 101, 106246.	1.8	14
15	Characteristics of Food Allergic Reactions in United States Restaurants. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1675-1682.	3.8	16
16	A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 676-683.e1.	3.8	11
17	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
18	A 300 IR sublingual tablet is an effective, safe treatment for house dust mite&induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. Journal of Allergy and Clinical Immunology, 2021, 147, 1020-1030.e10.	2.9	50

#	ARTICLE	IF	CITATIONS
19	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EGALEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
20	Allergen Immunotherapy: A Long Way Gone and a Long Way to Go. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1839-1840.	3.8	0
21	Characterizing Biphasic Food-Related Allergic Reactions Through a US Food Allergy Patient Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3717-3727.	3.8	6
22	Oral Immunotherapy-Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4087-4094.e3.	3.8	10
23	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. <i>European Respiratory Journal</i> , 2021, 58, 2004605.	6.7	10
24	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
25	Strategies for choosing a biologic for your patient with allergy or asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 627-637.	1.0	18
26	Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1165-1173.	10.7	70
27	Incidence of anaphylaxis and accidental peanut exposure: A systematic review. <i>Clinical and Translational Allergy</i> , 2021, 11, e12064.	3.2	8
28	Using a computer-tailored COPD screening assessment to promote advice-seeking behaviors. <i>World Allergy Organization Journal</i> , 2021, 14, 100603.	3.5	2
29	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
30	Real-World Assessment of Asthma Control and Severity in Children, Adolescents, and Adults with Asthma: Relationships to Care Settings and Comorbidities. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 989-996.e1.	3.8	18
31	Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1900964.	6.7	4
32	An expert consensus framework for asthma remission as a treatment goal. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 757-765.	2.9	144
33	Reply to "The association between free testosterone and current asthma". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3245.	3.8	0
34	The Role of Aeroallergen Sensitization Testing in Asthma Management. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2526-2532.	3.8	8
35	Airway relaxation mechanisms and structural basis of osthole for improving lung function in asthma. <i>Science Signaling</i> , 2020, 13, .	3.6	6
36	Coronavirus Disease (COVID)-19: World Health Organization Definitions and Coding to Support the Allergy Community and Health Professionals. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2144-2148.	3.8	18

#	ARTICLE	IF	CITATIONS
37	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2673-2680.e3.	3.8	15
38	Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2920-2936.e1.	3.8	14
39	Elevated Testosterone Is Associated with Decreased Likelihood of Current Asthma Regardless of Sex. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3029-3035.e4.	3.8	18
40	Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 244-249.	2.9	45
41	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines' Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	5.7	67
42	Commonly Used Adjuvant Human Vaccines: Advantages and Side Effects. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2953-2957.	3.8	18
43	Global implementation of the world health organization's International Classification of Diseases (ICD)â€11: The allergic and hypersensitivity conditions model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2206-2218.	5.7	25
44	Allergic Endotypes and Phenotypes of Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 429-440.	3.8	144
45	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq1 1 0.784314 rgBT /O recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	5.7	232
46	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€•recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	5.7	85
47	Adherence to adding inhaled corticosteroids to rescue therapy in a pragmatic trial with adults with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 487-493.e1.	1.0	8
48	Acute At Home Management of Anaphylaxis During the Covid-19 Pandemic. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1795-1797.	3.8	45
49	A roadmap for optimal care of the patient with food allergy. <i>Journal of Food Allergy</i> , 2020, 2, 1-2.	0.2	3
50	American Academy of Allergy, Asthma and Immunology response to the <sc>EAACI</sc>/<sc>GA</sc>²<sc>LEN</sc>/<sc>EDF</sc>/<sc>WAO</sc> guideline for the definition, classification, diagnosis, and management of Urticaria 2017 revision. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 411-413.	5.7	17
51	Omaliuzumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 156-164.e1.	3.8	173
52	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from <i>in vitro</i> allergen-release data. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 921-928.	3.0	7
53	Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. <i>Respiratory Research</i> , 2019, 20, 159.	3.6	15
54	Biologics, Clinical Context, and the Asthmas. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1437-1439.	3.8	2

#	ARTICLE	IF	CITATIONS
55	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
56	Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. <i>Respiratory Medicine</i> , 2019, 158, 97-109.	2.9	17
57	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
58	New insights into the utility of omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 923-926.e1.	2.9	39
59	Harmonization of Terminology for Tolerated and Reactive Dose in Food Allergy Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 389-392.	3.8	10
60	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseasesâ€“11. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 627-633.	2.9	46
61	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2336.	2.9	0
62	Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2425-2428.e7.	3.8	14
63	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101
64	Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapyâ€“An NIAID/AHRQ Workshop. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1711-1726.	2.9	20
65	Soy isoflavones reduce asthma exacerbation in asthmatic patients with high PAI-1â€“producing genotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 109-117.e4.	2.9	16
66	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
67	Validation of Patient-Reported Outcomes for Clinical Trials in Allergic Rhinitis: A Systematic Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1450-1461.e6.	3.8	27
68	Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 721-723.e9.	3.8	7
69	<sc>ARIA</sc> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€: <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
70	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
71	Upregulated P-Rex1 exacerbates human airway smooth muscle hyperplasia in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 778-781.e5.	2.9	3
72	Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1298-1305.e3.	3.8	11

#	ARTICLE	IF	CITATIONS
73	Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 122-130.e1.	3.8	44
74	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
75	Uses of biologics in allergic diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 357-366.	1.0	24
76	Allergic rhinitis management: what's next?. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 191-196.	3.0	7
77	Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 549-550.	1.0	2
78	Zika virus: An emerging infectious disease with serious perinatal and neurologic complications. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 482-490.	2.9	9
79	Critical view of anaphylaxis epidemiology: open questions and new perspectives. <i>Allergy, Asthma and Clinical Immunology</i> , 2018, 14, 12.	2.0	59
80	Efficacy of tiotropium in adults with moderate asthma, by leukotriene receptor antagonist use at baseline. <i>Allergy International</i> , 2018, 67, 411-413.	3.3	2
81	Impact of Baseline IgE levels on Exacerbations and Asthma Symptom Control After Omalizumab Initiation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, AB195.	2.9	2
82	Nasal Carbon Dioxide Used As Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 183-189.	3.8	4
83	Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 490-497.	5.7	121
84	Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 923-935.e9.	3.8	64
85	AR101 Oral Immunotherapy for Peanut Allergy. <i>New England Journal of Medicine</i> , 2018, 379, 1991-2001.	27.0	518
86	Can Xolair Be Used in Nonallergic Asthmatic?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2170.	3.8	0
87	The challenge of choosing the correct biologic for the correct asthma patient. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 385-386.	1.0	0
88	Potential new targets for drug development in severe asthma. <i>World Allergy Organization Journal</i> , 2018, 11, 30.	3.5	27
89	Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1108-1117.	3.8	47
90	Biological therapies for eosinophilic asthma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 747-754.	3.1	38

#	ARTICLE	IF	CITATIONS
91	Electronic Clinical Decision Support System for allergic rhinitis management: MASK eâ€CDSS. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1640-1653.	2.9	61
92	Investigational new drugs for allergic rhinitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 279-292.	4.1	24
93	Biologics and biomarkers for asthma, urticaria, and nasal polyposis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1411-1421.	2.9	60
94	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€™2016 revision. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 950-958.	2.9	1,199
95	Biologic and New Therapies in Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 329-343.	1.9	40
96	Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 18.	5.3	14
97	Perspectives on the International Classification of Diseases, 11th Revision, developments in allergy clinical practice in the United States. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 127-132.	1.0	10
98	The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 640-648.	3.8	16
99	Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 524-532.e2.	1.0	27
100	Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical Trials. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1717-1727.e1.	3.8	8
101	Biologic Therapy and Novel Molecular Targets of Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 909-916.	3.8	69
102	Biologics in Chronic Urticaria. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 95-112.	1.9	7
103	Validation of the Global Allergy and Asthma European Network (GA 2 LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1158-1166.	2.9	32
104	Sublingual Immunotherapy for the Polyallergic Patient. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 41-45.	3.8	15
105	Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 84-89.e3.	3.8	34
106	A call to arms of specialty societies to review the WHO International Classification of Diseases, Eleventh Revision terms appropriate for the diseases they manage: The example of the Joint Allergy Academies. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 54-55.	2.2	12
107	Severe asthma and quality of life. <i>World Allergy Organization Journal</i> , 2017, 10, 28.	3.5	63
108	Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1194-1204.e4.	3.8	22

#	ARTICLE	IF	CITATIONS
109	Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. <i>Respiratory Research</i> , 2016, 17, 103.	3.6	24
110	Updating Allergy and/or Hypersensitivity Diagnostic Procedures in the WHO ICD-11 Revision. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 650-657.	3.8	32
111	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
112	Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitisâ€”PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1347-1358.	2.9	249
113	Smoothing the transition from International Classification of Diseases, Tenth Revision, Clinical Modification to International Classification of Diseases, Eleventh Revision. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1265-1267.	3.8	18
114	Characterization of asthma endotypes: implications for therapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 121-125.	1.0	103
115	Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions. <i>Drugs</i> , 2016, 76, 999-1013.	10.9	4
116	Allergen immunotherapy for allergic asthma: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 5.	3.2	15
117	Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 643-649.	3.8	25
118	Sublingual grass and ragweed immunotherapy: Clinical considerationsâ€”a PRACTALL consensus report. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 369-376.	2.9	37
119	Anti-immunoglobulin E (IgE) Therapy. , 2016, , 623-637.		0
120	Allergy Immunotherapy. , 2016, , 639-650.		0
121	Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). <i>Allergy and Asthma Proceedings</i> , 2015, 36, 100-104.	2.2	23
122	Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets for Treatment of Allergic Rhinitis with/without Conjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB281.	2.9	2
123	The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. <i>Allergy, Asthma and Clinical Immunology</i> , 2015, 11, 17.	2.0	17
124	<sc>CYT</sc>003, a <sc>TLR</sc>9 agonist, in persistent allergic asthma â€” a randomized placeboâ€”controlled Phase 2b study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1160-1168.	5.7	55
125	The Use of Anti-IgE Therapy Beyond Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 162-166.	3.8	45
126	Estimated Asthma Exacerbation Reduction from Omalizumab in an Severe Eosinophilic Asthma Population. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB1.	2.9	4

#	ARTICLE	IF	CITATIONS
127	Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 743-750.e1.	3.8	61
128	Role of biologics in intractable urticaria. <i>Biologics: Targets and Therapy</i> , 2015, 9, 25.	3.2	15
129	“The value of pre- and co- seasonal sublingual immunotherapy in pollen- induced allergic rhinoconjunctivitis”, <i>Clinical and Translational Allergy</i> , 2015, 5, 18.	3.2	23
130	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 367-376.	10.7	153
131	The Electronic Cigarette: The Good, the Bad, and the Ugly. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 498-505.	3.8	46
132	COPD: The Not So Good, the Bad, and the Ugly!. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 519-520.	3.8	0
133	Regulator of G-Protein Signaling 2 Repression Exacerbates Airway Hyper-Responsiveness and Remodeling in Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 42-49.	2.9	24
134	The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1119-1140.	5.7	31
135	Omalizumab for Chronic Urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 118-119.	3.8	1
136	Hymenoptera-Sting Hypersensitivity. <i>New England Journal of Medicine</i> , 2014, 370, 1432-1439.	27.0	45
137	Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1365-1372.e6.	2.9	268
138	Tiotropium Respimat® Add-On Therapy Reduces Airflow Obstruction In Patients With Symptomatic Moderate Asthma, Independent Of TH2 Inflammatory Status. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB5.	2.9	5
139	Novel Approaches of Immunotherapy. <i>Current Treatment Options in Allergy</i> , 2014, 1, 58-67.	2.2	3
140	The Efficacy and Safety Of The Short Ragweed Sublingual Immunotherapy Tablet MK-3641 Is Similar In Asthmatic and Nonasthmatic Subjects Treated For Allergic Rhinitis With/Without Conjunctivitis (AR/C). <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB218.	2.9	2
141	Rates Of Comorbidities Are Related To Level Of Asthma Control. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB80.	2.9	0
142	Efficacy Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria With Different Background Therapy: Post Hoc Analysis Of Asteria I, Asteria II, and Glacial Studies. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB117.	2.9	2
143	Alcohol Exposure and Airway Hyperresponsiveness. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB143.	2.9	0
144	Immunotherapy: What lies beyond. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 612-619.	2.9	91

#	ARTICLE	IF	CITATIONS
145	Rates Of Co-Morbidities Are Related To Asthma Severity. Journal of Allergy and Clinical Immunology, 2014, 133, AB80.	2.9	0
146	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	6.7	154
147	Anti-Immunoglobulin E Therapy. , 2014, , 1480-1490.		0
148	Assessment of disease control in allergic rhinitis. Clinical and Translational Allergy, 2013, 3, 7.	3.2	67
149	Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. Journal of Allergy and Clinical Immunology, 2013, 131, 1342-1349.e6.	2.9	147
150	Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine, 2013, 368, 924-935.	27.0	838
151	Aquagenic Urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 295-296.	3.8	3
152	Effects of Cigarette Smoke Exposure On RGS2 Expression and Airway Hyperresponsiveness. Journal of Allergy and Clinical Immunology, 2013, 131, AB61.	2.9	0
153	Allergy Immunotherapy Safety: Location Matters!. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 455-457.	3.8	15
154	Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	2.9	144
155	An evidence-based analysis of house dust mite allergen immunotherapy: A call for more rigorous clinical studies. Journal of Allergy and Clinical Immunology, 2013, 132, 1322-1336.	2.9	124
156	Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. Journal of Allergy and Clinical Immunology, 2013, 131, 1288-1296.e3.	2.9	396
157	Characteristics of Asthma Patients Seeking Specialist Care. Journal of Allergy and Clinical Immunology, 2013, 131, AB107.	2.9	1
158	Comparison of Characteristics of Asthma Patients Seeking Care From Specialists Versus Primary Care Physicians. Journal of Allergy and Clinical Immunology, 2013, 131, AB34.	2.9	1
159	Anaphylaxis to cat in a child with exclusive sensitivity to Fel d 1. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 416-417.	3.8	3
160	Characteristics of Asthma Visits to Specialists Compared to Primary Care Physicians. Journal of Allergy and Clinical Immunology, 2013, 131, AB34.	2.9	1
161	Omalizumab for treatment of allergic rhinitis. Expert Opinion on Biological Therapy, 2013, 13, 933-945.	3.1	44
162	Relationship of Airway Hyperresponsiveness and RGS2 Expression in Smokers. Journal of Allergy and Clinical Immunology, 2013, 131, AB12.	2.9	0

#	ARTICLE	IF	CITATIONS
163	RGS2 repression increases susceptibility of mice to interleukin-13-induced airway hyperresponsiveness. <i>FASEB Journal</i> , 2013, 27, 1095.8.	0.5	0
164	Targeting Phosphoinositide 3-Kinase β in Airway Smooth Muscle Cells to Suppress Interleukin-13-Induced Mouse Airway Hyperresponsiveness. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 305-311.	2.5	20
165	Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1327-1334.e1.	2.9	120
166	Relationship of 25-hydroxyvitamin D and asthma control in children. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 281-282.	1.0	35
167	We call for iCAALL: International Collaboration for Asthma, Allergy and Immunology. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 108, 215-216.	1.0	1
168	Long-Acting β_2 -Agonist Step-off in Patients With Controlled Asthma. <i>Archives of Internal Medicine</i> , 2012, 172, 1365.	3.8	54
169	Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 929-934.	2.9	157
170	The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 409-412.e2.	2.9	55
171	We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 904-905.	2.9	10
172	Statement regarding "The public health benefits of air pollution control". <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 24.	2.9	7
173	Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 311-324.	2.9	18
174	Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 968-976.e3.	2.9	40
175	Future of Allergy/Immunology Task Force Report. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1009-1010.	2.9	8
176	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1049-1062.	2.9	486
177	The use of the peroxisome proliferator-activated receptors β agonist rosiglitazone to treat airway hyperreactivity. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 75-77.	1.0	9
178	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach " A MeDALL " GA<sup>2</sup></sup>LEN " ARIA Position Paper. <i>International Archives of Allergy and Immunology</i> , 2012, 158, 216-231.	2.1	83
179	Principles of pharmacotherapy. , 2012, , 147-169.		2
180	Practical guide to skin prick tests in allergy to aeroallergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 18-24.	5.7	475

#	ARTICLE	IF	CITATIONS
181	We call for <scp>ICAALL</scp>: International Collaboration in Asthma, Allergy and Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 449-450.	5.7	5
182	Monoclonal antibodies for chronic refractory asthma and pipeline developments. Drug Discovery Today, 2012, 17, 591-599.	6.4	11
183	International consensus on (ICON) pediatric asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 976-997.	5.7	327
184	Targeting phosphoinositide 3-kinase β in airway smooth muscle cells to suppress interleukin-13-induced mouse airway hyperresponsiveness. FASEB Journal, 2012, 26, 667.4.	0.5	0
185	Nasal carbon dioxide for the symptomatic treatment of perennial allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2011, 107, 364-370.	1.0	9
186	Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. Journal of Allergy and Clinical Immunology, 2011, 127, 30-38.	2.9	168
187	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA2LEN) article. Journal of Allergy and Clinical Immunology, 2011, 127, 49-56.e11.	2.9	42
188	Future forms of immunotherapy. Journal of Allergy and Clinical Immunology, 2011, 127, 8-15.	2.9	83
189	Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. Journal of Allergy and Clinical Immunology, 2011, 127, 355-360.	2.9	1,007
190	Future Forms of Immunotherapy and Immunomodulators in Allergic Disease. Immunology and Allergy Clinics of North America, 2011, 31, 343-365.	1.9	9
191	Allergic rhinitis and asthma: celebrating 100 years of immunotherapy. Current Opinion in Immunology, 2011, 23, 808-813.	5.5	12
192	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 765-774.	5.7	67
193	Immune modulation for treatment of allergic disease. Immunological Reviews, 2011, 242, 258-271.	6.0	78
194	Expression and Function of a Novel Variant of Estrogen Receptor β 36 in Murine Airways. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1084-1089.	2.9	22
195	Role of vitamin D in asthma. Therapy: Open Access in Clinical Medicine, 2011, 8, 297-306.	0.2	3
196	G β 13-activated phosphoinositide 3-kinase β regulates airway smooth muscle contraction by modulating calcium oscillations. FASEB Journal, 2011, 25, 1011.4.	0.5	0
197	Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	5.7	85
198	Immunomodulators for Asthma. Allergy, Asthma and Immunology Research, 2010, 2, 228.	2.9	12

#	ARTICLE	IF	CITATIONS
199	Probiotic Prophylaxis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1058-1064.	5.6	308
200	Phosphoinositide 3-Kinase \hat{I}^3 Regulates Airway Smooth Muscle Contraction by Modulating Calcium Oscillations. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 703-709.	2.5	32
201	Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 383-389.	2.9	199
202	Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial. Journal of Allergy and Clinical Immunology, 2010, 126, 666-668.e5.	2.9	94
203	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. Journal of Allergy and Clinical Immunology, 2010, 126, 466-476.	2.9	1,322
204	The role of vitamin D in asthma. Annals of Allergy, Asthma and Immunology, 2010, 105, 191-199.	1.0	116
205	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	5.6	1,591
206	Clinical importance of identifying immunoglobulin E-mediated disease in patients with Asthma. Clinical Cornerstone, 2009, 9, 20-29.	0.7	3
207	Should clinicians routinely determine rhinitis subtype on initial diagnosis and evaluation? A debate among experts. Clinical Cornerstone, 2009, 9, 54-60.	0.7	9
208	Immunomodulators in asthma therapy. Current Allergy and Asthma Reports, 2009, 9, 475-483.	5.3	12
209	Safety and tolerability of omalizumab. Clinical and Experimental Allergy, 2009, 39, 788-797.	2.9	216
210	Sublingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
211	Anti-IgE therapy: Clinical utility beyond asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 770-771.e1.	2.9	26
212	Unmet needs in severe chronic upper airway disease (SCUAD). Journal of Allergy and Clinical Immunology, 2009, 124, 428-433.	2.9	191
213	Recommendations for appropriate sublingual immunotherapy clinical trials. Journal of Allergy and Clinical Immunology, 2009, 124, 665-670.	2.9	77
214	OMALIZUMAB IN IDIOPATHIC ANAPHYLAXIS. Annals of Allergy, Asthma and Immunology, 2009, 102, 257-258.	1.0	70
215	Utility and limitations of objective measures of asthma. Annals of Allergy, Asthma and Immunology, 2009, 102, 518-522.	1.0	2
216	LIMITATIONS OF OBJECTIVE MEASURES OF ASTHMA. Annals of Allergy, Asthma and Immunology, 2009, 102, 530-531.	1.0	1

#	ARTICLE	IF	CITATIONS
217	Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 103, 31-37.	1.0	26
218	Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 612-623.	2.2	12
219	Sub-Lingual Immunotherapy. <i>World Allergy Organization Journal</i> , 2009, 2, 233-281.	3.5	100
220	Anti-IgE Therapy. , 2009, , 1679-1689.		2
221	Allergic Rhinitis, Asthma, and Obstructive Sleep Apnea: The Link. , 2009, , 129-140.		0
222	Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 953-961.	5.7	85
223	Intranasal noninhaled carbon dioxide for the symptomatic treatment of seasonal allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 105-109.	2.9	25
224	Immunomodulators for allergic respiratory disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 288-296.	2.9	64
225	Asthma and obesity. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 641-643.	1.0	2
226	DYSPNEA AND OBESITY IN AFRICAN AMERICAN WOMEN. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 644-645.	1.0	3
227	Time-dependent inhibition of histamine-induced cutaneous responses by oral and intramuscular diphenhydramine and oral fexofenadine. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 100, 452-456.	1.0	18
228	Guidelines for Treatment of Pediatric Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2855.	7.4	1
229	A new perspective on concepts of asthma severity and control. <i>European Respiratory Journal</i> , 2008, 32, 545-554.	6.7	372
230	Anti-Immunoglobulin E Therapy. <i>World Allergy Organization Journal</i> , 2008, 1, 174-183.	3.5	11
231	Cultured Lung Fibroblasts from Ovalbumin-Challenged "Asthmatic" Mice Differ Functionally from Normal. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 424-430.	2.9	45
232	Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 688-695.	2.9	122
233	Sublingual immunotherapy and subcutaneous immunotherapy: Issues in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1466-1468.	2.9	10
234	Omalizumab in the Treatment of Allergic Respiratory Disease. <i>Journal of Asthma</i> , 2006, 43, 87-93.	1.7	6

#	ARTICLE	IF	CITATIONS
235	Identifying and managing rhinitis and its subtypes: allergic and nonallergic components – a consensus report and materials from the Respiratory & Allergic Disease Foundation. <i>Current Medical Research and Opinion</i> , 2006, 22, 2541-2548.	1.9	59
236	Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 60-68.	1.0	37
237	Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 454-456.	1.0	39
238	Necrotizing pneumonia with a questionable lung mass in a 59-year-old man. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 116-121.	1.0	0
239	Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 134-140.	2.9	329
240	Allergy Immunotherapy for Primary Care Physicians. <i>American Journal of Medicine</i> , 2006, 119, 820-823.	1.5	13
241	Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma. <i>Chest</i> , 2006, 129, 1176-1187.	0.8	46
242	CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of FcεRI. <i>Clinical and Experimental Allergy</i> , 2006, 36, 1436-1445.	2.9	34
243	Managing impairment in patients with allergic rhinitis. <i>Allergy and Asthma Proceedings</i> , 2006, 27, 12-6.	2.2	13
244	Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2006, 27, S33-6.	2.2	9
245	PROBIOTIC MANIPULATION OF THE NATIVE FLORA IN CRITICALLY ILL PATIENTS: AN OPPORTUNITY FOR VENTILATOR-ASSOCIATED PNEUMONIA PROPHYLAXIS?. <i>Chest</i> , 2005, 128, 144S.	0.8	8
246	Omalizumab in Asthma: Approval and Postapproval Experience. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 29, 003-016.	6.5	12
247	The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 459-465.	2.9	425
248	Pediatric Allergic Rhinitis: Treatment. <i>Immunology and Allergy Clinics of North America</i> , 2005, 25, 283-299.	1.9	20
249	Rationale for new treatments aimed at IgE immunomodulation. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 212-217.	1.0	37
250	Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 297-302.	2.9	254
251	Status of immunotherapy: Current and future. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1036-1039.	2.9	25
252	Anti-IgE therapy. <i>Immunology and Allergy Clinics of North America</i> , 2004, 24, 551-568.	1.9	30

#	ARTICLE	IF	CITATIONS
253	Clinical Implications of the Allergic Rhinitis-Asthma Link. American Journal of the Medical Sciences, 2004, 327, 127-138.	1.1	72
254	Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma. Annals of Allergy, Asthma and Immunology, 2003, 90, 323-330.	1.0	13
255	First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2003, 111, S835-S842.	2.9	123
256	Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study. Annals of Allergy, Asthma and Immunology, 2003, 90, 79-86.	1.0	12
257	Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2003, 91, 160-167.	1.0	197
258	Omalizumab treatment downregulates dendritic cell Fc̳RI expression. Journal of Allergy and Clinical Immunology, 2003, 112, 1147-1154.	2.9	328
259	Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2003, 111, 87-90.	2.9	179
260	CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. Journal of the American Academy of Dermatology, 2003, 49, 816-825.	1.2	91
261	The Role of Anti-IgE in Asthma. , 2003, , 215-221.		0
262	Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy and Asthma Proceedings, 2003, 24, 323-9.	2.2	37
263	Small airway inflammation: a new therapeutic target in asthma. Introduction. Postgraduate Medicine, 2003, 113, 5-6.	2.0	0
264	The pathophysiology of small airway inflammation in asthma. Postgraduate Medicine, 2003, 113, 7-12.	2.0	2
265	Asthma: imaging of the smaller airways. Postgraduate Medicine, 2003, 113, 13-4.	2.0	0
266	Small airway asthma therapy, challenges, and the future. Postgraduate Medicine, 2003, 113, 15-20.	2.0	0
267	A Comparison of Methods for Assessing Hypothalamic-Pituitary-Adrenal (HPA) Axis Activity in Asthma Patients Treated with Inhaled Corticosteroids. Journal of Clinical Pharmacology, 2002, 42, 319-326.	2.0	24
268	Therapeutic resolution of late allergic response and airway hyperresponsiveness by Flt-3 ligand in a mouse model of allergic inflammation. Journal of Allergy and Clinical Immunology, 2002, 109, S24-S24.	2.9	0
269	Next generation antihistamines: therapeutic rationale, accomplishments and advances. Expert Opinion on Investigational Drugs, 2002, 11, 807-817.	4.1	38
270	INHALED FLUTICASONE IN ASTHMATIC CHILDREN. Annals of Allergy, Asthma and Immunology, 2002, 89, 329.	1.0	0

#	ARTICLE	IF	CITATIONS
271	Immunomodulation of asthma: Where do we stand?. Current Allergy and Asthma Reports, 2002, 2, 433-435.	5.3	0
272	Treatment of Seasonal Allergic Rhinitis. Lung Biology in Health and Disease, 2002, , 299-325.	0.1	0
273	Experience with monoclonal antibodies in allergic mediated disease: Seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 2001, 108, S84-S88.	2.9	33
274	Long-Term Safety of Flunisolide Hydrofluoroalkane Metered-Dose Inhaler in Adults and Adolescents with Asthma. Clinical Drug Investigation, 2001, 21, 755-764.	2.2	8
275	Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Annals of Allergy, Asthma and Immunology, 2001, 87, 379-385.	1.0	82
276	Allergic Rhinitis/Asthma Interrelationships. Clinical Reviews in Allergy and Immunology, 2001, 21, 27-50.	6.5	20
277	Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis. A Randomized Controlled Trial. JAMA - Journal of the American Medical Association, 2001, 286, 2956.	7.4	322
278	Anti-Immunoglobulin E (Omalizumab) Therapy in Seasonal Allergic Rhinitis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, S18-S21.	5.6	32
279	Cannabis (hemp) positive skin tests and respiratory symptoms. Annals of Allergy, Asthma and Immunology, 2000, 85, 238-240.	1.0	45
280	Safety and Efficacy of Once-Daily Fexofenadine HCl in the Treatment of Autumn Seasonal Allergic Rhinitis. Allergy and Asthma Proceedings, 1999, 20, 193-198.	2.2	58
281	Combination of IL-8 Plus TNF α Induces Additive Neutrophil Migration. Allergy and Asthma Proceedings, 1999, 20, 361-364.	2.2	12
282	Cytokine-induced sequential migration of neutrophils through endothelium and epithelium. Inflammation Research, 1999, 48, 22-27.	4.0	19
283	Demonstration of therapeutic equivalence of generic and innovator beclomethasone in seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology, 1999, 82, 435-441.	1.0	16
284	Eosinophils isolated by magnetic cell sorting respond poorly to lipid chemoattractants. Annals of Allergy, Asthma and Immunology, 1999, 83, 127-131.	1.0	9
285	Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology, 1999, 83, 311-317.	1.0	106
286	Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. Journal of Allergy and Clinical Immunology, 1999, 104, 46-52.	2.9	66
287	Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: A controlled trial. Journal of Allergy and Clinical Immunology, 1998, 101, 7-13.	2.9	13
288	The Sequential Migration of Neutrophils Through Endothelium and Epithelium: A New Model System. Experimental Lung Research, 1998, 24, 709-719.	1.2	5

#	ARTICLE	IF	CITATIONS
289	Tumor Necrosis Factor α Is Necessary for Granulocyte-Macrophage-Colony-Stimulating-Factor-Induced Eosinophil Transendothelial Migration. <i>International Archives of Allergy and Immunology</i> , 1998, 115, 24-32.	2.1	9
290	Interleukin-8 plays a significant role in IgE-mediated lung inflammation. <i>European Respiratory Journal</i> , 1998, 11, 299-305.	6.7	24
291	Orientation and presence of epithelium are key to endotoxin-induced neutrophil migration. <i>European Respiratory Journal</i> , 1998, 11, 1053-1059.	6.7	3
292	Cytokine-induced Neutrophil Transepithelial Migration Is Dependent upon Epithelial Orientation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1997, 17, 727-732.	2.9	23
293	Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 100, 110-121.	2.9	326
294	Human Lung Anaphylaxis Results in Rapid Release of Interleukin-4. <i>Annals of Allergy, Asthma and Immunology</i> , 1997, 78, 566-568.	1.0	1
295	Intranasal therapy with once-daily triamcinolone acetonide aerosol versus twice-daily beclomethasone dipropionate aqueous spray in patients with perennial allergic rhinitis. <i>Current Therapeutic Research</i> , 1996, 57, 825-838.	1.2	2
296	Effects of in Vitro Mast Cell Degranulation on Human Lung β_2 -Receptor Binding Parameters. <i>Annals of Allergy, Asthma and Immunology</i> , 1996, 77, 140-146.	1.0	0
297	Isolation technique alters eosinophil migration response to IL-8. <i>Journal of Immunological Methods</i> , 1996, 197, 97-107.	1.4	13
298	Cytokines induce selective granulocyte chemotactic responses. <i>Inflammation Research</i> , 1996, 45, 89-95.	4.0	29
299	Eosinophil migration in response to three molecular species of platelet activating factor. <i>Inflammation Research</i> , 1996, 45, 265-267.	4.0	6
300	Speed of onset of action of Tilarin. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1996, 51, 14-19.	5.7	6
301	Neutrophil transepithelial migration is dependent upon epithelial characteristics.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1996, 15, 224-231.	2.9	23
302	TNF alpha is important in human lung allergic reactions.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1996, 15, 35-44.	2.9	64
303	Comparative studies indicate that platelet-activating factor is a relatively weak eosinophilotactic mediator.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1995, 12, 65-70.	2.9	9
304	Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1995, 268, L117-L122.	2.9	61
305	Interleukin-8 mediates interleukin-1 alpha-induced neutrophil transcellular migration.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1995, 13, 323-329.	2.9	35
306	The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1734-1739.	5.6	174

#	ARTICLE	IF	CITATIONS
307	5-Hydroxyeicosatetraenoic acid (HETE)-induced neutrophil transcellular migration is dependent upon enantiomeric structure.. American Journal of Respiratory Cell and Molecular Biology, 1995, 12, 260-267.	2.9	34
308	TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1994, 266, L238-L245.	2.9	62
309	Allergic Models and Cytokines. American Journal of Respiratory and Critical Care Medicine, 1994, 150, S72-S76.	5.6	28
310	Report of successful desensitization to itraconazole. Journal of Allergy and Clinical Immunology, 1994, 94, 270-271.	2.9	7
311	Pulmonary epithelial cells facilitate TNF-alpha-induced neutrophil chemotaxis. A role for cytokine networking. Journal of Immunology, 1994, 152, 4087-94.	0.8	52
312	Platelet-activating Factor-induced Human Eosinophil Transendothelial Migration: Evidence for a Dynamic Role of the Endothelium. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 77-82.	2.9	20
313	Effects of neuropeptides on neutrophil migration through noncellular and endothelial barriers. Journal of Allergy and Clinical Immunology, 1993, 92, 589-598.	2.9	82
314	Nedocromil sodium is rapidly effective in the therapy of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 1993, 91, 997-1004.	2.9	20
315	Acute Effects of In Vitro Mast Cell Degranulation on Human Lung Muscarinic Receptors. The American Review of Respiratory Disease, 1993, 147, 940-945.	2.9	10
316	Interleukin-8-induced Transcellular Neutrophil Migration Is Facilitated by Endothelial and Pulmonary Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1993, 9, 489-495.	2.9	44
317	Degree of Neutrophil Chemotaxis Is Dependent upon the Chemoattractant and Barrier. American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 112-117.	2.9	34
318	Comparison of methodologies to measure human lung histamine. Journal of Immunological Methods, 1992, 152, 115-121.	1.4	8
319	Effects of various barriers on platelet-activating factor-induced neutrophil chemotaxis. Journal of Allergy and Clinical Immunology, 1991, 87, 565-574.	2.9	11
320	Validity of skin tests to cyclophosphamide and metabolites. Journal of Allergy and Clinical Immunology, 1991, 88, 965-967.	2.9	7
321	Neuropeptides and the lung. Journal of Allergy and Clinical Immunology, 1991, 88, 1-14.	2.9	36
322	Comparison of platelet-activating factor-induced chemotaxis of normodense and hypodense eosinophils. Journal of Allergy and Clinical Immunology, 1991, 88, 187-192.	2.9	19
323	Cutaneous responses to anticholinergics: Evidence for muscarinic receptor subtype participation. Journal of Allergy and Clinical Immunology, 1991, 87, 971-976.	2.9	15
324	Mast Cell Hyperplasia in Experimental Hypersensitivity Pneumonitis. International Archives of Allergy and Immunology, 1991, 96, 168-174.	2.1	4

#	ARTICLE	IF	CITATIONS
325	Comparison of leukotriene B4-induced neutrophil migration through different cellular barriers. <i>American Journal of Physiology - Cell Physiology</i> , 1990, 258, C639-C647.	4.6	29
326	The effects of intravenous endotoxin on various host-effector molecules. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 85, 45-51.	2.9	20
327	Degree of platelet activating factor-induced neutrophil migration is dependent upon the molecular species. <i>Journal of Immunology</i> , 1990, 145, 2561-5.	0.8	17
328	Use of Segmental Airway Lavage to Obtain Relevant Mediators from the Lungs of Asthmatic and Control Subjects. <i>Chest</i> , 1989, 95, 1059-1063.	0.8	33
329	Elevated BAL Fluid Histamine Levels and Parenchymal Pulmonary Disease in Rheumatoid Arthritis. <i>Chest</i> , 1989, 96, 1016-1021.	0.8	9
330	Azelastine inhibits stimulated histamine release from human lung tissue in vitro but does not alter cyclic nucleotide content. <i>Agents and Actions</i> , 1989, 28, 16-21.	0.7	23
331	The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. <i>Journal of Allergy and Clinical Immunology</i> , 1989, 83, 771-776.	2.9	35
332	Azelastine inhibits IgE-mediated human basophil histamine release. <i>Journal of Allergy and Clinical Immunology</i> , 1989, 83, 862-865.	2.9	45
333	[3H]quinuclidinyl benzilate binding to the human lung muscarinic receptor. <i>Biochemical Pharmacology</i> , 1988, 37, 973-976.	4.4	9
334	Guide to physical urticarias. <i>Journal of Allergy and Clinical Immunology</i> , 1988, 82, 758-763.	2.9	65
335	Bronchoalveolar Lavage Fluid Histamine Levels in Interstitial Lung Diseases. <i>The American Review of Respiratory Disease</i> , 1988, 138, 1604-1608.	2.9	36
336	Characterization of muscarinic receptor subtypes on human peripheral lung. <i>Journal of Applied Physiology</i> , 1988, 65, 594-600.	2.5	29
337	Airway reactivity to methacholine in nonatopic asymptomatic adults. <i>Journal of Applied Physiology</i> , 1988, 64, 2558-2561.	2.5	20
338	(3 H)[125I]Pindolol binding to human peripheral lung beta-receptors. <i>Biochemical Pharmacology</i> , 1987, 36, 2557-2564.	4.4	8
339	Comparison of two radiolabeled quinuclidinyl benzilate ligands for the characterization of the human peripheral lung muscarinic receptor. <i>Life Sciences</i> , 1987, 41, 1577-1584.	4.3	4
340	Airway responses to methacholine in asymptomatic nonatopic cigarette smokers. <i>Journal of Applied Physiology</i> , 1987, 62, 1888-1892.	2.5	29
341	Immunohistochemical identification of lung cells responsive to beta-stimulation with a rise in cAMP. <i>Journal of Applied Physiology</i> , 1987, 63, 434-439.	2.5	8
342	Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. <i>Journal of Clinical Investigation</i> , 1987, 79, 1197-1203.	8.2	205

#	ARTICLE	IF	CITATIONS
343	Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction.. Journal of Clinical Investigation, 1987, 80, 1507-1511.	8.2	139
344	Neuromechanisms of asthma. Annals of Allergy, 1987, 59, 391-8.	0.5	11
345	Exercise-Induced Anaphylactic Syndromes. JAMA - Journal of the American Medical Association, 1986, 255, 2049.	7.4	61
346	Exercise-induced anaphylactic syndromes. Insights into diagnostic and pathophysiologic features. JAMA - Journal of the American Medical Association, 1986, 255, 2049-2053.	7.4	57
347	Characterization of histamine H-1 receptors on human mononuclear cells. International Journal of Immunopharmacology, 1985, 7, 639-645.	1.1	18
348	Characterization of histamine H-1 receptors on human peripheral lung. Biochemical Pharmacology, 1985, 34, 3285-3292.	4.4	43
349	Alpine Slide Anaphylaxis. New England Journal of Medicine, 1984, 310, 1034-1037.	27.0	17
350	Preparation of a human lung purified plasma membrane fraction: Confirmation by enzyme markers, electron microscopy, and histamine H1 receptor binding. Journal of Membrane Biology, 1984, 79, 33-39.	2.1	7
351	Demonstration that circulating human blood cells have no detectable alpha-adrenergic receptors by radioligand binding analysis. Journal of Allergy and Clinical Immunology, 1984, 74, 812-818.	2.9	36
352	Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: Evidence for opiate and nonopiate receptor participation. Journal of Allergy and Clinical Immunology, 1984, 73, 775-781.	2.9	193
353	Dopamine inhibition of histamine-mediated cutaneous responses. Journal of Allergy and Clinical Immunology, 1984, 73, 837-841.	2.9	7
354	Concomitant Pulmonary Aspergillosis and Nocardiosis in a Patient With Chronic Granulomatous Disease of Childhood. Southern Medical Journal, 1984, 77, 274-275.	0.7	26
355	Detection of beta-adrenergic receptors on rabbit mononuclear cells isolated free of significant contamination by other cell types. Life Sciences, 1983, 33, 971-977.	4.3	4
356	Chromobactehum violaceum Infectious and Chronic Granulomatous Disease. Annals of Internal Medicine, 1983, 98, 259.	3.9	11
357	The role of the autonomic nervous system in allergic diseases. Annals of Allergy, 1983, 51, 423-9.	0.5	10
358	Chronic Granulomatous Disease of Childhood and Chromobacterium violaceum Infections in the Southeastern United States. Annals of Internal Medicine, 1982, 97, 51.	3.9	98
359	Aplastic anemia. Postgraduate Medicine, 1982, 71, 59-70.	2.0	1
360	Complete hematologic and hepatic recovery in a patient with chloramphenicol hepatitis-pancytopenia syndrome. Journal of Pediatrics, 1982, 101, 1025-1027.	1.8	6

#	ARTICLE	IF	CITATIONS
361	A rapid method for isolation of human mononuclear cells free of significant platelet contamination. Journal of Immunological Methods, 1982, 55, 347-353.	1.4	23
362	Right bundle-branch block. Occurrence following nonpenetrating chest trauma without evidence of cardiac contusion. JAMA - Journal of the American Medical Association, 1979, 242, 172-173.	7.4	7